Features
CAR T-Cell Therapy Brings New Hope to Cancer Patients at Stanford Health Care
CAR T-cell therapy offers a new treatment option for patients with certain blood cancers who did not response to other treatments.
Find the latest information on COVID-19, monkeypox, and the flu vaccine
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Working with many rare forms of blood disorders, the Stanford Hematology Program brings together a multispecialty team of experts dedicated to treating leukemia as well as other benign and malignant hematologic disorders.
Offering state-of-the-art chemotherapy protocols for leukemia and other hematologic malignancies, as well as working seamlessly with Stanford's highly-acclaimed Blood and Marrow Transplant Program, the Hematology Program strives to assure the best possible outcome for patients. Our goal is to improve the survival and quality of life of patients, and Stanford hematologists were instrumental in the development of the National Comprehensive Cancer Network (NCCN) guidelines for the management of hematologic malignancies.
A specialized therapy to transfer healthy bone marrow cells into a patient after their own unhealthy bone marrow has been eliminated.
The use of anticancer drugs to shrink or kill cancerous cells and reduce cancer spreading to other parts of the body.
Immunotherapy (also called biological therapy, biological response modifier therapy, or biotherapy) is designed to boost the body's immune system in order to fight cancer. The cells, antibodies, and organs of the immune system work to protect and defend the body against foreign invaders, such as bacteria or viruses. Doctors and researchers have found that the immune system might also be able to both determine the difference between healthy cells and cancer cells in the body, and to eliminate the cancer cells.
The use of high-energy radiation to kill or shrink cancer cells, tumors, and non-cancerous diseases.
A method of replacing blood-forming cells destroyed by cancer treatment to help the bone marrow recover and continue to make healthy blood cells.
CAR T-cell therapy offers a new treatment option for patients with certain blood cancers who did not response to other treatments.
Beverly Mitchell, MD, talks about why she became a doctor and what she loves about her field.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Bring completed forms found in the Hematology New Patient Letter.
Please fax the Medical Record Release Form to your new patient coordinator. The medical release form is an authorization form for external facilities to release medical records to Stanford Health Care.
International Patients
Phone: +1 650-723-8561
Email: IMS@stanfordhealthcare.org
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or e-mail the Referral Center at ReferralCenter@stanfordhealthcare.org
Email or fax a cancer referral form with supporting documentation to ReferralCenter@stanfordhealthcare.org or 650-320-9443.